Mirror sites (1:1 microsites) for Series B companies: scaling without breaking for healthcare and life sciences in Latin America
How Series B companies scale mirror sites (1:1 microsites) across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Latin America.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Latin America. In this market, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms, so the way you install mirror sites (1:1 microsites) has to be shaped to that reality from day one.
Series B is the stress test for mirror sites (1:1 microsites). What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.
The Series B move is to separate the model owner from the operators. One senior human owns strategy, meeting rate from account-specific URLs, and the weekly review; a small team runs the machine.
Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Latin America it is compounded by the fact that local partnership depth, not marketing spend is what actually gates growth. Mirror sites (1:1 microsites) is only useful here when it is pointed at both constraints at once.
Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.
The Series B failure mode of mirror sites (1:1 microsites) is using them as brochures instead of sales rooms, amplified by headcount. Fix the root cause; do not paper over it with more people.
Compensation begins to matter now. Pay operators on meeting rate from account-specific URLs outcomes, not on effort. Effort-based comp at Series B produces theatre.
A well-run mirror sites (1:1 microsites) function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.
Concretely for healthcare and life sciences in Latin America: the healthcare teams that install this get past procurement instead of dying in it, and one properly-installed LATAM account becomes a reference across the region. That is the reason it is worth installing mirror sites (1:1 microsites) deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Microsites · healthcare · LATAM — answered
- Does mirror sites (1:1 microsites) work for healthcare and life sciences in Latin America?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms. The healthcare teams that install this get past procurement instead of dying in it.
- How does mirror sites (1:1 microsites) change at Series B?
- Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
- When should we expand to a second region?
- After the first region delivers two straight quarters of defensible meeting rate from account-specific URLs.
- What compensation model works for mirror sites (1:1 microsites) operators at Series B?
- Outcome-linked on meeting rate from account-specific URLs, not activity-based.
- What is the Series B stress point?
- Using them as brochures instead of sales rooms, amplified by headcount. Fix the root, not the symptom.
- What is the LATAM-specific pitfall when running mirror sites (1:1 microsites) for healthcare?
- Importing a playbook that was built for another market. In Latin America, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms — the install has to reflect that.
Growth Broker editorial
Filed under microsites · healthcare · latam